A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada in Antiretroviral Therapy naive HIV-1 Infected Patients (VERxVE).

Trial Profile

A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada in Antiretroviral Therapy naive HIV-1 Infected Patients (VERxVE).

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2014

At a glance

  • Drugs Nevirapine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms VERxVE
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Mar 2012 Planned number of patients changed from 1033 to 1250 as reported by European Clinical Trials Database.
    • 18 Jan 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top